These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 2848896)
21. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of lymphokine-activated killer cell function by human alveolar macrophages. Roth MD; Golub SH Cancer Res; 1989 Sep; 49(17):4690-5. PubMed ID: 2788029 [TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL; Herberman RB; Hiserodt JC Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411 [TBL] [Abstract][Full Text] [Related]
25. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Brooks B; Rees RC Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652 [TBL] [Abstract][Full Text] [Related]
26. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes. Schwarz RE; Hiserodt JC J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421 [TBL] [Abstract][Full Text] [Related]
27. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells]. Zheng YJ; Zhang J; Wang SM; Zhang JR Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306 [TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture. Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989 [TBL] [Abstract][Full Text] [Related]
31. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213 [TBL] [Abstract][Full Text] [Related]
32. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1. Espevik T; Figari IS; Ranges GE; Palladino MA J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680 [TBL] [Abstract][Full Text] [Related]
34. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. Lee RK; Spielman J; Zhao DY; Olsen KJ; Podack ER J Immunol; 1996 Sep; 157(5):1919-25. PubMed ID: 8757310 [TBL] [Abstract][Full Text] [Related]
35. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
36. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Owen-Schaub LB; Gutterman JU; Grimm EA Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408 [TBL] [Abstract][Full Text] [Related]
37. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887 [TBL] [Abstract][Full Text] [Related]
38. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. Yang JC; Mulé JJ; Rosenberg SA J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187 [TBL] [Abstract][Full Text] [Related]